FDA officially denies IBD indication for Salix drug

Salix Pharmaceuticals didn't win the FDA's blessing to market Xifaxan as a remedy for irritable bowel syndrome, a potentially lucrative new use for the drug, which is now approved for traveler's diarrhea. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.